Evidence map›Paper›PMID 38230592›Full record

ReviewJournal of menopausal medicine2023

Tibolone and Breast Cancer.

Jae Kyung Lee, Hyewon Yun, Heeyon Kim, Bo Hyon Yun, Seok Kyo Seo

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of menopausal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jae Kyung LeeDepartments of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
Hyewon YunDepartments of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
Heeyon KimDepartments of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
Bo Hyon YunDepartments of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
Seok Kyo SeoDepartments of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-3404-0484
Yonsei University · KR

Funding

Korea Health Industry Development Institute HA23C046503
6 · The paper itself

Abstract

Tibolone, a selective tissue estrogenic activity regulator, is a synthetic steroid with distinct pharmacological and clinical characteristics in contrast to conventional menopausal hormone therapy. Tibolone induces estrogenic activity in the brain, vagina, and bone but remains inactive in the endometrium and breast. In particular, several studies have investigated whether tibolone usage increases the risk of breast cancer. This study aims to determine the effects of tibolone on the breast by focusing on the relation between tibolone use and breast cancer. Our investigation emphasizes recent studies, particularly those based on Asian populations.

Indexed as

Breast densityBreast neoplasmsPostmenopausal hormone replacement therapyTibolone

Identifiers

PMID38230592
PMCPMC10796206
OpenAlexW4298866294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.